Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExBAT Trial in mCRPC
NCT04558866Phase 2Completed
- Sponsor
- Latin American Cooperative Oncology Group
- Start
- Jun 2021
- Primary completion
- Mar 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide, testosterone cypionate in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Latin American Cooperative Oncology Group. Started Jun 2021; status: completed.
02
Drugs
darolutamidetestosterone cypionate
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04558866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04558866.